Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AstraZeneca Plc

The Best Stock to Buy for Under $100 Right Now

Strong fundamentals and bright prospects of AstraZeneca (AZN), trading below $100 a share, could help investors secure decent risk-adjusted returns on their investments in a choppy market environment. Read on….

StockNews.com

2 Pharma Stocks to Buy Right Now and 1 You Might Want to Consider Selling

The pharmaceutical industry is evolving with personalized medicines and the rapid adoption of RPM technology, which should boost growth. Moreover, with a recession lurking, fundamentally strong pharma stocks AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) might be ideal buys. However, SNDL (SNDL) might be best avoided. Keep reading to know why.

StockNews.com

Pfizer’s RSV vaccine just won an FDA panel’s backing for safety in older people. It's a market that will be worth up to $10 billion in a decade

Pfizer is also facing off with collaborators Sanofi and AstraZeneca Plc to develop prevention for dangerous RSV infections in newborns, a market that could reach $1.5 billion.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

2 Large-Cap Stocks You Can Buy for Under $100

While rising inflation and the Fed’s rate hikes are expected to keep the stock market volatile in the near term, large-cap stocks could help survive. Therefore, fundamentally sound large-cap stocks, Coca-Cola (KO) and AstraZeneca (AZN), which are currently trading under $100, might be solid additions to your portfolio. Keep reading.

StockNews.com

1 Pharma Stock Poised for a Promising 2023

Following a year of solid growth in 2022, leading pharma company AstraZeneca’s (AZN) robust pipeline and recent launches look promising. Moreover, its strong fundamentals should enable the stock to deliver solid returns this year. So, AZN could be an ideal buy. Keep reading.

StockNews.com

4 Pharma Stocks to Buy Now for the Long Haul

The pharma industry has experienced tremendous growth in recent years. The industry should continue to grow, driven by the growing market for personalized medicine and e-pharmacies. Hence, pharma stocks Pfizer (PFE), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and Zoetis (ZTS) might be worth buying for the long term. Also, these companies…

StockNews.com

Boost Your Portfolio With These Strong Buy Stocks

Expectations of the economy avoiding a recession have been rising amid the still-tight labor market and improving consumer sentiments. However, while uncertainties remain, quality stocks Walmart (WMT), AstraZeneca (AZN), and LSI Industries (LYTS), which are Strong Buy-rated in our proprietary system, could be ideal additions to boost your portfolios. Keep…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Stocks to Help You Build Wealth in the Market

Receding inflationary pressure and the Fed’s smaller rate hike have raised investor optimism. However, amid additional rate hike fears and associated volatilities, investors could scoop up quality stocks Johnson & Johnson (JNJ), Coca-Cola (KO), and AstraZeneca (AZN) that could help them build wealth in the market. Read on….

StockNews.com

3 Pharma Stocks to Buy in 2023 and Hold for Decades

The pharmaceutical industry is well-positioned for significant growth in the near future, given the growing demand for medicines and increasing R&D activities. Given the industry's inelastic demand, fundamentally strong pharma stocks AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and GSK plc (GSK) might be solid long-term investments. Continue reading….

StockNews.com

2 Pharma Stocks to Buy Now for Big Gains

The pharma industry is well-placed to benefit from the rise of chronic diseases and an aging population. Moreover, given the stable demand for medicines, the industry is relatively unaffected by macroeconomic uncertainty. Therefore, it could be wise for investors to buy fundamentally strong pharma stocks AstraZeneca (AZN) and Novartis (NVS).…

StockNews.com

4 Pharmaceutical Stocks You Can Always Rely On

The pharmaceutical industry is well-positioned to witness substantial growth, driven by the prevalence of chronic diseases, the aging population, and increased healthcare spending. Given the industry’s promising growth prospects, we think it could be wise to invest in fundamentally sound pharmaceutical stocks Johnson & Johnson (JNJ), Merck & Co (MRK),…

StockNews.com

5 Amazing Stocks You Won’t Ever Regret Buying

Easing inflation and the Fed’s indication of slowing the pace of interest rate hikes are raising investors’ sentiments. Moreover, the November job report came in better than expected. While uncertainties remain, we think quality stocks Pfizer (PFE), AstraZeneca PLC (AZN), Carrier Global (CARR), J. Jill (JILL), and Lifeway Foods (LWAY)…

StockNews.com

2 Biotech Stocks to Buy and Hold for the Long Term

Intensive innovation, breakthrough developments, and growing investments should help the biotech industry witness solid growth over the next decade. And given the sector’s reputation as a safe haven amid economic turmoil, it could be wise for investors to buy and hold fundamentally solid biotech stocks Amgen (AMGN) and AstraZeneca (AZN)…

StockNews.com

AstraZeneca top heart drug sees potential to reach more patients

One of AstraZeneca Plc’s top-selling drugs Farxiga, a diabetes treatment, is beneficial to a wider pool of patients than previously indicated, a study shows, bolstering the product’s blockbuster potential.

Tribune News Service

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Recap of Monday's Biotech Catalysts - End Of the Day Summary

Kodiak Sciences Inc. (NASDAQ:KOD) announced positive topline results its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab) in patients with macular edema due to retinal vein occlusion. Kodiak shares traded in a range of $10.02 to $11.79 on a day volume of 4.05 million shares, closed regular trading session…

Benzinga

Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral Pact

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Oxford Biomedica Inks New Three Year Deal To Make AstraZeneca's COVID-19 Vaccine

Oxford Biomedica plc (OTC:OXBDF) signed a new three-year agreement to potentially make AstraZeneca Plc's (NASDAQ:AZN) COVID-19 vaccine beyond 2022. The new agreement represents an expansion of the original master supply and development agreement announced between the two companies in September 2020. The manufacture of COVID-19 vaccines at Oxford Biomedica's Oxbox facility, as part of the…

Benzinga

AstraZeneca Says Imfinzi/Chemo Combo Shows Promising Action In Late-Stage Lung Cancer Study

AstraZeneca Plc (NASDAQ:AZN) announced high-level results from a planned interim analysis of the AEGEAN Phase 3 trial of Imfinzi (durvalumab) combined with neoadjuvant chemotherapy in patients with resectable non-small cell lung cancer (NSCLC). The data showed that Imfinzi plus neoadjuvant chemo before surgery demonstrated a statistically significant and meaningful improvement in pathologic complete…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

AstraZeneca's ALXN1840 Shows Promising Action Against Copper Metabolism Disorder

AstraZeneca Plc (NASDAQ:AZN) announced detailed results from the positive FoCus Phase 3 trial of ALXN1840 in Wilson's disease, an inherited condition in which the body's pathway for removing excess copper is compromised. The data showed that ALXN1840 met its primary endpoint demonstrating three-times greater copper mobilization from tissues compared to the standard of…

Benzinga

Short Volatility Alert: AstraZeneca PLC

On Tuesday, shares of AstraZeneca PLC (NASDAQ: AZN) experienced volatile short activity. After the activity, the stock price went up 2.85% to $62.83. The overall sentiment for AZN has been Bullish.

Benzinga

Why Mereo BioPharma Shares Are Jumping Today

AstraZeneca plc (NASDAQ:AZN) is rumored to be eyeing take over of Mereo BioPharma Group plc (NASDAQ:MREO), according to a report in The Times. The Times' report says that "Mereo would accept $5, equating to $500 million including American depositary receipts or ADRs. Evercore and Citigroup are said to be involved as advisers." Mereo's lead…

Benzinga

Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share

Innoviva Inc (NASDAQ:INVA) has agreed to acquire Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) at $2.20 per share in cash. Innoviva currently owns approximately 60% of the outstanding shares of Entasis common stock. The acquisition consideration values Entasis' equity at $113 million on a fully diluted basis. "This acquisition will build upon our overall strategy to acquire differentiated,…

Benzinga

AstraZeneca In-Licenses New Suite Of COVID-19 Antibody Candidate(s)

AstraZeneca plc (NASDAQ:AZN) moved to bolster its COVID-19 portfolio of antibodies with a $157 million licensing deal for experimental therapies developed by newly-launched UK-based biotech, RQ Biotechnology Ltd. In addition to the initial sum, AstraZeneca will pay possible royalty payments as part of the exclusive license to develop pre-clinical COVID antibodies engineered by RQ…

Benzinga

AstraZeneca's Combination Inhaler Shines In Phase 3 Asthma Trial

AstraZeneca Plc (NASDAQ:AZN) posted full results from the positive MANDALA Phase 3 trial of PT027, an albuterol/budesonide fixed-dose combination rescue medication in patients with asthma. The data exhibited that PT027 at two different strengths of budesonide demonstrated a statistically significant reduction in the risk of a severe exacerbation versus albuterol rescue. Compared with…

Benzinga

Almost 400M COVID-19 Vaccine Doses Lost Due To Emergent's Baltimore Plant Fiasco

According to a recent report from the US House select subcommittee on the coronavirus crisis, Emergent Biosolutions Inc (NYSE:EBS) might have destroyed nearly 400 million doses of COVID-19 vaccines after failing to meet quality standards. Initially, 75 million - 85 million doses of drug substance were said to be destroyed after contamination. "Despite major…

1 2 3

People

Sristi Suman Jayaswal

90 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.